vTv Therapeutics Inc - Class A - Real-time stock metrics, market data, and comprehensive analysis
Fetching stock data...
vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv's clinical pipeline is led by cadisegliatin, a potential adjunctive therapy to insulin for the treatment of type 1 diabetes. vTv and its development partners are investigating additional indications including type 2 diabetes and other chronic conditions.
No news available
Have a question or want to work together? Fill out the form below and we’ll get back to you as soon as possible.
